ArticleApplied microbiology and biotechnology2026
A newly isolated Streptomyces nigra strain for the biotechnological production of melanin.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioreactor-based production of eumelanin nanoparticles by Streptomyces glaucescens NEAE-H: physicochemical characterization, anticancer and anti-inflammatory activities, and in silico analysis.Scientific reports · 2026Article
- Optimized melanin production from marine-associated Bacillus sp. EGY7 as a sustainable precursor of carbon dots for biomedical applications.Bioresources and bioprocessing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Melanins are pigments widely distributed in microbial, plant, and animal kingdoms. Their UV-visible light shielding capacity, metal chelation ability, antioxidant, and antimicrobial properties make these pigments suitable for different industrial applications like in cosmetic and bioremediation fields. The actual manufacturing process relies on the extraction from animal tissues like the ink of Sepia officinalis and/or on synthetic chemical procedures. Streptomycetes might be the ideal candidates for the development of biotechnological processes of melanin production due to their ability to produce pigments as secondary metabolites, extracellularly released. Here, a new strain of Streptomyces nigra, capable of efficiently producing eumelanin, was isolated from soil samples in Messina, Sicily, Italy, and characterized first by 16S rRNA analysis and then by whole genome sequencing, with a complete gene clusters analysis. The strain ability of growing and producing melanin was tested on four media, including newly formulated ones, and by also optimizing temperature and pH conditions of growth, a melanin production of 2.45 ± 0.01 g/L was reached. The pigment, once produced under the optimal conditions, was purified and characterized by UV-visible, FT-IR, NMR, and EPR spectroscopy, revealing an eumelanin-like structure. KEY POINTS: • A new Streptomyces nigra strain, MT6, was isolated and identified • A new formulated medium boosted melanin production up to 2.45 g/L • The extracellular pigment was characterized as eumelanin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.